Abstract
The review by Ted Sourkes and Serge Gauthier describe the status quo of drug developments in Parkinson's disease (PD) as of 1983. Remarkably, levodopa is still the most effective medication for the treatment of this devastating disorder. Progress has been made since then, though, in developing new formulations of levodopa in order to treat patients with more severe symptomology. In addition, inhibitors of monoamine oxidase, selegiline and rasagiline, have been synthesized and together with inhibitors of catechol-O-methyltransferase, tolcapone, entacapone, opicapone, allow reduction of the dose of daily levodopa. In addition, these compounds contribute to reduce oxidative stress. In contrast to 1983, as only piribedil is mentioned in the original review, a number of dopamine receptor agonists have been marketed, but only apomorphine, pramipexol, ropinirol, rotigotine and piripedil are of major importance today. The mode of action of amantadine has been discovered and since then, this drug has become a valuable addition to treatment strategies for early PD, mild symptomology and therapy of levodopa-induced dyskinesias. As such, the groundbreaking developments in PD therapy as described by Sourkes and Gauthier have been further elucidated and extended, but we are waiting for the next breakthrough in therapy to cure or at least to halt the degenerative processes underlying PD.
Originalsprog | Engelsk |
---|---|
Titel | Discoveries in Pharmacology : Nervous system and hormones |
Redaktører | Michael Parnham, Clive Page, Jacques Bruinvels, M.J. Parnham |
Vol/bind | 1 |
Forlag | Academic Press |
Publikationsdato | 1. jan. 2023 |
Udgave | 2. |
Sider | 173-178 |
Kapitel | 8A |
ISBN (Trykt) | 9780323855204 |
ISBN (Elektronisk) | 9780323855198 |
DOI |
|
Status | Udgivet - 1. jan. 2023 |
Bibliografisk note
Publisher Copyright:© 2023 Elsevier Inc. All rights reserved.